Our History

The reason why

ZeClinics was founded to challenge how preclinical research was performed. We believed preclinical drug discovery and development should be more predictive, so clinical trials would have better chances of success. And we believed preclinical research should be faster and more efficient, so patients would benefit earlier from discoveries. The aims were ambitious, but our reasons were simple: we wanted to bring better drugs to patients in a shorter time.

We knew that zebrafish could provide faster results and better biological translatability than other preclinical models. And we knew our expertise using this amazing tiny fish could provide solutions to those huge challenges. That was the start of this amazing journey.

But the road doesn’t end here. Innovation is at our core and we keep disrupting the drug discovery field by combining zebrafish biology with lab automation and artificial intelligence. Because we want to provide even faster and more reliable preclinical research. And we know how to do it.

2013-2014

ZeClinics is born. Thanks to the support of the Universitat Pompeu Fabra, the company set up its laboratory in the Barcelona Biomedical Research Park, where it began providing services to international clients, attracted by their innovative research model.

2015-2016

ZeClinics is a pioneer in the Barcelona biomedical ecosystem by completing the first round of crowdfunding through the Capital Cell Platform. Revenues from the service activity continue to grow steadily, and the granting of several fellowships and grants allows the company to expand its scientific and commercial team.

2017 - 2019

ZeClinics is awarded a SME instrument Phase 2 from the H2020 Program worth 1.8 million euros. This grant allows us to implement lab automation processes in our research. It also allows the development of ZeCardio, a platform to analyze cardiovascular parameters in a high-throughput manner. ZeClinics experiences substantial growth in terms of team size and number of ongoing projects. We open a new office to host the commercial and administrative growing team.

2019 - 2021

The ZeClinics research team moves to IGTP, where the company acquires a larger laboratory space to accommodate its growing scientific team. We also built our own fish facility at the nearby CMCIB. In 2019 the company found its first spin off,  ZeCardio Therapeutics, a pharmaceutical company seeking to discover drugs related to cardiovascular diseases. In 2020, ZeCardio Therapeutics managed to raise 800,000 euros despite the COVID-19 pandemic. The company continues its growth in terms of number of developed projects, number of clients and team. Currently, ZeClinics consists of more than 30 people, most of whom are  international scientists with PhDs.

The reason why

ZeClinics was founded to challenge how preclinical research was performed. We believed preclinical drug discovery and development should be more predictive, so clinical trials would have better chances of success. And we believed preclinical research should be faster and more efficient, so patients would benefit earlier from discoveries. The aims were ambitious, but our reasons were simple: we wanted to bring better drugs to patients in a shorter time.

We knew that zebrafish could provide faster results and better biological translatability than other preclinical models. And we knew our expertise using this amazing tiny fish could provide solutions to those huge challenges. That was the start of this amazing journey.

But the road doesn’t end here. Innovation is at our core and we keep disrupting the drug discovery field by combining zebrafish biology with lab automation and artificial intelligence. Because we want to provide even faster and more reliable preclinical research. And we know how to do it.

2013-2014

ZeClinics is born. Thanks to the support of the Universitat Pompeu Fabra, the company set up its laboratory in the Barcelona Biomedical Research Park, where it began providing services to international clients, attracted by their innovative research model.

2015-2016

ZeClinics is a pioneer in the Barcelona biomedical ecosystem by completing the first round of crowdfunding through the Capital Cell Platform. Revenues from the service activity continue to grow steadily, and the granting of several fellowships and grants allows the company to expand its scientific and commercial team.

2017 - 2019

ZeClinics is awarded a SME instrument Phase 2 from the H2020 Program worth 1.8 million euros. This grant allows us to implement lab automation processes in our research. It also allows the development of ZeCardio, a platform to analyze cardiovascular parameters in a high-throughput manner. ZeClinics experiences substantial growth in terms of team size and number of ongoing projects. We open a new office to host the commercial and administrative growing team.

2019 - 2021

The ZeClinics research team moves to IGTP, where the company acquires a larger laboratory space to accommodate its growing scientific team. We also built our own fish facility at the nearby CMCIB. In 2019 the company found its first spin off,  ZeCardio Therapeutics, a pharmaceutical company seeking to discover drugs related to cardiovascular diseases. In 2020, ZeCardio Therapeutics managed to raise 800,000 euros despite the COVID-19 pandemic. The company continues its growth in terms of number of developed projects, number of clients and team. Currently, ZeClinics consists of more than 30 people, most of whom are  international scientists with PhDs.

Our team

The most important asset of the company and a large factor in our success is our team. We have recruited specialist scientists and created a friendly working culture that includes flexible working hours and a profit-sharing scheme for our staff, which has produced an environment of continual growth and innovation.

The investment of time and effort that ZeClinics has put into building a healthy company culture is because we are convinced that this encourages intellectual freedom, an open mind and spirit, and ultimately better innovation.

We are all working together to generate better, safer, and more efficient biomedical research for the benefit of society.

We support your R&D project to make your research easier, faster and more successful
our-team https://www.zeclinics.com/wp-content/uploads/2021/08/our-history-team.jpg

We are proud to be able to count on motivated scientists covering all the different phases of drug discovery from library screening to model generation and validation, safety and efficacy assessment. We are experts in zebrafish biology and the application of the zebrafish model.

We like to highlight that most of our scientists have a PhD. They are flexible, able to work on both basic and applied research projects and have a broad vision of the business of bringing science to clinical practice.

ZeClinics Governance
Board
of Directors

Javier Terriente Davide D'Amico Simone Calzolari Ignasi Sahún Elisabet Mateu Vincenzo Di Donato

Javier Terriente ZeCardioTX
davide-damico davide-damico
simone-calzolari simone-calzolari
ignasi-sahun ignasi-sahun
CFO Advisory
(external)

Miguel Ezcurra

miguel-ezcurra-duotono miguel-ezcurra
Scientifc Advisory Board

Florian Engert Filippo Del Bene

engert_florian_color
filippo-del-bene-color